
## Casual Friday Series


# GI ResQ Protocol 101: Multiple Applications







# The Wedge Protocol



## Microbial dysbiosis in the gut drives systemic autoimmune diseases

Walaa K Mousa 1,2,3,\*,†, Fadia Chehadeh 1, Shannon Husband 1

PMCID:

Trillions of microbes survive and thrive inside the human body. These tiny creatures are crucial to the development and maturation of our immune system and to maintain gut immune homeostasis. Microbial dysbiosis is the main driver of local inflammatory and autoimmune diseases such as colitis and inflammatory bowel diseases. Dysbiosis in the gut can also drive systemic autoimmune diseases such as type 1 diabetes, rheumatic arthritis, and multiple sclerosis. Gut microbes directly interact with the immune system by multiple mechanisms including modulation of the host microRNAs affecting gene expression at the post-transcriptional level or production of microbial metabolites that interact with cellular receptors such as TLRs and GPCRs. This interaction modulates crucial immune functions such as differentiation of lymphocytes, production of interleukins, or controlling the leakage of inflammatory molecules from the gut to the systemic circulation. In this review, we compile and analyze data to gain insights into the underpinning mechanisms mediating systemic autoimmune diseases. Understanding how gut microbes can trigger or protect from systemic autoimmune diseases is crucial to (1) tackle these diseases through diet or lifestyle modification, (2) develop new microbiome-based therapeutics such as prebiotics or probiotics, (3) identify diagnostic biomarkers to predict disease risk, and (4) observe and intervene with microbial population change with the flare-up of autoimmune responses. Considering the microbiome signature as a crucial player in systemic autoimmune diseases might hold a promise to turn these untreatable diseases into manageable or preventable ones.




## Microbial dysbiosis in the gut drives systemic autoimmune diseases

Walaa K Mousa 1,2,3,\*,†, Fadia Chehadeh 1, Shannon Husband 1

Microbial dysbiosis disturbs the immune function leading to inflammation and sensitization of the immune system and causing autoimmune diseases (35, 36). Many factors influence microbial dysbiosis such as diet, stress, drugs, diseases, age, and lifestyle. The imbalance in helper T cells/regulatory T cells drives autoimmune diseases such as colitis and multiple sclerosis (MS) (18, 33). Leakage of metabolites such as lipopolysaccharides sensitizes the immune system, leading to a higher production of pro-inflammatory interleukins, and degradation of mucin resulting in irritation of the gut lining and microbial invasion (37). Figure 1 illustrates the role of some microbial taxa in maintaining gut barrier function and how microbial dysbiosis results in a leaky gut. Each microbe prevents or drives inflammation by a unique mechanism. For example, Faecalibacterium prausnitzii prevents inflammation by inducing Treg differentiation, leading to the subsequent higher production of IL-10 (an antiinflammatory interleukin) (38, 39). In contrast, Fusobacterium nucleatum drives inflammation by inhibiting cytotoxic T cells and modulation of miRNAs, leading to suppression of autophagy (28). Several examples of individual microbes that modulate host immune response to prevent or drive inflammation and autoimmune reaction are noted (40-72) and summarized (Table 2).





Lactobacilli and Bifidobacterium increase bile salt hydrolyses, leading to GLP-1 hormone stimulation. If this microbial role is disturbed, inflammation and autoimmune diseases arise.




# GI ResQ Protocol












#### Relative Commensal Abundance



## Additional Results

Methodology: Fecal Immunochemical Testing (FIT)

Fecal Occult Blood+

Positive


**Expected Value** 

Negative

Color†† Brown

Consistency†† Formed/Normal





Lactobacilli and Bifidobacterium increase bile salt hydrolyses, leading to GLP-1 hormone stimulation. If this microbial role is disturbed, inflammation and autoimmune diseases arise.




## **Strategy Adaptations**









https://pmc.ncbi.nlm.nih.gov/articles/PMC6689741/

## **Strategy Adaptations**








#### **Functional Imbalance Scores** : Low Need for Support (2-3) (4-6): Moderate Need for Support (7-10): High Need for Support : Optional Need for Support Key Need for Need for Need for Need for Need for **Digestive Support** Inflammation Modulation Microbiome Support **Prebiotic Support Antimicrobial Support** MALDIGESTION INFLAMMATION DYSBIOSIS METABOLIC IMBALANCE INFECTION 6 Secretory IgA PP Bacteria/Yeast Total SCFA's PP Bacteria/Yeast Pancreatic Elastase Reference Variance Calprotectin n-Butyrate Conc. Parasitic Infection Products of Protein Breakdown Eosinophil Protein X IAD/Methane Score SCFA (%) Pathogenic Bacteria Fecal Fats Occult Blood Total Abundance Beta-glucuronidase Total Abundance Elimination Diet/ Food Pre-/Probiotics Pre-/Probiotics Therapeutic Support Options · Digestive Enzymes Antibiotics Sensitivity Testing · Increase Dietary Fiber · Increased Dietary Fiber Betaine HCI (if warranted) · Mucosa Support: Slippery Intake Intake Bile Salts Antimicrobial Herbal Elm, Althea, Aloe, DGL, etc. Consider SIBO Testing · Increase Resistant · Apple Cider Vinegar Therapy Zinc Carnosine · Mindful Eating Habits Increase Resistant Starches · Antiparasitic Herbal L-Glutamine Starches Increase Fermented Digestive Bitters Therapy (if warranted) Quercetin Increase Fermented Foods Saccharomyces Foods Calcium D-Glucarate Turmeric boulardii Omega-3's Meal Timing (for high · GI Referral (If Calpro is beta-glucuronidase) Elevated)



#### **Relative Commensal Abundance**



Digestion and Absorption					
Pancreatic Elastase 1 †	88 L	100 •	200		>200 mcg/g
Products of Protein Breakdown (Total*) (Valerate, Isobutyrate, Isovalerate)	3.2	•		+	1.8-9.9 micromol/g
Fecal Fat (Total*)	14.3	-	<b>→</b> +		3.2-38.6 mg/g
Triglycerides	0.4	<b>+</b> +		-	0.3-2.8 mg/g
Long-Chain Fatty Acids	8.3		<b>•</b>		1.2-29.1 mg/g
Cholesterol	5.2 <b>H</b>	-		-	0.4-4.8 mg/g
Phospholipids	0.4	<b>+</b> +		-	0.2-6.9 mg/g



## Bacteriology (Culture)

Lactobacillus spp.

Escherichia coli

Bifidobacterium (Anaerobic Culture)

# NG 4+ NP 4+ NP 4+ NP

#### **Additional Bacteria**

Salmonella spp.


Shigella spp.

Klebsiella oxytoca

Hafnia alvei

gamma haemolytic Streptococcus

beta Strep (Not Group A or B)





## **Strategy Adaptations**







## **Key Principle**

Protocol specialization **requires data** for decision making.

- Blood
- Stool
- Symptoms Questionnaire





Reach out to your Biogenetix Rep.



Submit your case to the CC team

